What kind of ongoing medical care and therapies are typically involved in managing Pol III-related leukodystrophy?

Management is multidisciplinary and focuses on symptoms. This often includes physical, occupational, and speech therapy to address movement and communication difficulties. Dental care is crucial for the specific tooth abnormalities. Hormonal therapy may be needed for hypogonadotropic hypogonadism, and medications can help manage seizures or excessive salivation.

How does Pol III-related leukodystrophy typically progress over time, and what can families expect regarding the worsening of symptoms?

Pol III-related leukodystrophy is a progressive disorder, meaning symptoms generally worsen over time. Intellectual disability can advance from mild to severe, and ataxia (coordination problems) typically becomes more pronounced. Families can expect increasing challenges with mobility, speech, and daily activities, requiring ongoing adjustments to care and support.

What are the most serious complications or "red flags" that require immediate medical attention for someone with Pol III-related leukodystrophy?

Serious complications include choking due to dysphagia (difficulty swallowing) and dysarthria (speech impairment), which can lead to aspiration. Seizures, if they occur, require prompt medical management. Any sudden or significant worsening of neurological symptoms, such as increased difficulty with movement or vision, should also be evaluated urgently.

What are the key early signs of Pol III-related leukodystrophy that parents or caregivers should look for in a child?

Parents might first notice delayed motor milestones, such as difficulty sitting or walking, along with problems coordinating movements (ataxia) and tremors. Unique dental abnormalities like missing teeth (hypodontia), teeth present at birth (natal teeth), or unusually shaped teeth can also be early indicators.

Pol III-related leukodystrophy

Pol III-related leukodystrophy is a rare hypomyelinating disorder that leads to progressive neurological decline, movement coordination problems, dental abnormalities, and hormonal disturbances.

Overview

Pol III-related leukodystrophy is a disorder that affects the nervous system and other parts of the body. Leukodystrophies involve abnormalities of the white matter, which consists of nerve cells covered by myelin. Myelin insulates nerve fibers and promotes rapid transmission of nerve impulses.

This condition is a hypomyelinating disease, meaning the nervous system has a reduced ability to form myelin. Reduced myelin underlies most of the neurological problems associated with the disorder. Some individuals also exhibit cerebellar atrophy and hypoplasia of the corpus callosum, which likely contribute to the clinical picture.

Symptoms

Intellectual disability ranging from mild to severe, often progressive.
Ataxia (difficulty coordinating movements) beginning in childhood and worsening over time; delayed motor milestones and unstable gait.
Tremor of the arms and hands, which may be intention tremor or present at rest.
Dental abnormalities including hypodontia or oligodontia, natal teeth, delayed eruption of primary and permanent teeth, atypical tooth sequence, and unusually shaped teeth.
Salivation, dysphagia, and dysarthria leading to choking risk and speech impairment.
Eye movement abnormalities such as progressive vertical gaze palsy, nearsightedness, lens clouding (cataract), and optic nerve atrophy.
Seizures may occur.
Hypogonadotropic hypogonadism causing delayed puberty and reduced body hair development.
Cerebellar atrophy and hypoplasia of the corpus callosum in some individuals.

Frequency

Pol III-related leukodystrophy is a rare disorder; its prevalence is unknown. More than 100 affected individuals have been described in the medical literature.

Causes & Risk Factors

The disorder is caused by mutations in the POLR3A or POLR3B genes. These genes encode the two largest subunits of RNA polymerase III, an enzyme that synthesizes various forms of RNA, including ribosomal RNA (rRNA) and transfer RNA (tRNA). Mutations may impair assembly of the polymerase subunits or reduce the enzyme’s ability to bind DNA, leading to diminished RNA polymerase III function. This reduced function likely affects development and function of many body systems, including the nervous system and teeth, though the precise mechanisms linking the gene mutations to specific clinical features remain unknown.

Learn more about the genes associated with Pol III-related leukodystrophy

POLR3A
POLR3B

Inheritance

This condition is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations. Parents of an affected individual each carry one copy of the mutated gene but typically do not show signs or symptoms.

Other Names

4H syndrome
ADDH
Ataxia, delayed dentition, and hypomyelination
Dentoleukoencephalopathy
HCAHC
HLD7
HLD8
Hypomyelination with cerebellar atrophy and hypoplasia of the corpus callosum
Hypomyelination, hypodontia, hypogonadotropic hypogonadism
Leukodystrophy with oligodontia
Leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism
Leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism
Leukoencephalopathy-ataxia-hypodontia-hypomyelination
LO
Odontoleukodystrophy
Pol III disorder
Pol III-related hypomyelinating leukodystrophies
Ribonucleic acid polymerase III-related leukodystrophy
TACH
Tremor-ataxia with central hypomyelination

Additional Information & Resources

Genetic Testing Information

Genetic Testing Registry: POLR-related leukodystrophy

Patient Support and Advocacy Resources

National Organization for Rare Disorders (NORD)

Clinical Trials

ClinicalTrials.gov

Catalog of Genes and Diseases from OMIM

LEUKODYSTROPHY, HYPOMYELINATING, 7, WITH OR WITHOUT OLIGODONTIA AND/OR HYPOGONADOTROPIC HYPOGONADISM; HLD7
LEUKODYSTROPHY, HYPOMYELINATING, 8, WITH OR WITHOUT OLIGODONTIA AND/OR HYPOGONADOTROPIC HYPOGONADISM; HLD8

Scientific Articles on PubMed

PubMed

References

Bernard G, et al. Mutations of POLR3A encoding a catalytic subunit of RNA polymerase Pol III cause a recessive hypomyelinating leukodystrophy. Am J Hum Genet. 2011 Sep 9;89(3):415-23. doi:10.1016/j.ajhg.2011.07.014.
Cayami FK, et al. POLR3A and POLR3B Mutations in Unclassified Hypomyelination. Neuropediatrics. 2015 Jun;46(3):221-8. doi:10.1055/s-0035-1550148.
Daoud H, et al. Mutations in POLR3A and POLR3B are a major cause of hypomyelinating leukodystrophies with or without dental abnormalities and/or hypogonadotropic hypogonadism. J Med Genet. 2013 Mar;50(3):194-7. doi:10.1136/jmedgenet-2012-101357.
Potic A, et al. 4H syndrome with late-onset growth hormone deficiency caused by POLR3A mutations. Arch Neurol. 2012 Jul;69(7):920-3. doi:10.1001/archneurol.2011.1963.
Sato I, et al. A case with central and peripheral hypomyelination with hypogonadotropic hypogonadism and hypodontia (4H syndrome) plus cataract. J Neurol Sci. 2011 Jan 15;300(1-2):179-81. doi:10.1016/j.jns.2010.09.009.
Terao Y, et al. Diffuse central hypomyelination presenting as 4H syndrome caused by compound heterozygous mutations in POLR3A encoding the catalytic subunit of polymerase III. J Neurol Sci. 2012 Sep 15;320(1-2):102-5. doi:10.1016/j.jns.2012.07.005.
Tetreault M, et al. Recessive mutations in POLR3B, encoding the second largest subunit of Pol III, cause a rare hypomyelinating leukodystrophy. Am J Hum Genet. 2011 Nov 11;89(5):652-5. doi:10.1016/j.ajhg.2011.10.006.
Vanderver A, et al. More than hypomyelination in Pol-III disorder. J Neuropathol Exp Neurol. 2013 Jan;72(1):67-75. doi:10.1097/NEN.0b013e31827c99d2.
Wolf NI, et al. Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations. Neurology. 2014 Nov 18;83(21):1898-905. doi:10.1212/WNL.0000000000001002.